PREVAIL trial shows positive effects of Livalo(Kowa Hakko Kirin) over pravastatin in LDL-C

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company have announced results of the PREVAIL U.S. study which evaluated the efficacy of Livalo (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed Dyslipidemia. Study results were presented during two poster sessions at the National Lipid Association's (NLA) Scientific Sessions in Scottsdale, Arizona. Livalo 4 mg showed superior LDL-C reduction compared with pravastatin 40 mg after 12 weeks of therapy. In the first poster, Morgan R, Campbell S, et al, "Pitavastatin 4 mg is Superior to Pravastatin 40 mg in LDL-C Reduction: Results from PREVAIL US Trial in Primary Hyperlipidemia or Mixes Dyslipidemia"- subjects treated with Livalo 4 mg experienced a median percent reduction in LDL-C of 38.1% over the treatment period compared to a 26.4% median percent reduction in patients randomized to pravastatin 40 mg. Livalo reduced total cholesterol by 25.8%, with pravastatin showing a total cholesterol reduction of 18.3%. Livalo treated patients experienced a significant 26.9% reduction in Apo B compared with a 17.7% reduction associated with pravastatin. A second poster dealt with the positive effects of Livalo on other lipid parameters.